| Lung volume reduction for emphysema PL Shah, FJ Herth, WH van Geffen, G Deslee, DJ Slebos The Lancet Respiratory Medicine 5 (2), 147-156, 2017 | 134 | 2017 |
| Surgical and endoscopic interventions that reduce lung volume for emphysema: a systemic review and meta-analysis WH van Geffen, DJ Slebos, FJ Herth, SV Kemp, W Weder, PL Shah The Lancet Respiratory Medicine 7 (4), 313-324, 2019 | 94 | 2019 |
| Increased levels of (class switched) memory B cells in peripheral blood of current smokers CA Brandsma, MN Hylkema, M Geerlings, WH van Geffen, DS Postma, ... Respiratory research 10, 1-11, 2009 | 87 | 2009 |
| Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD. WH van Geffen, WR Douma, D Slebos, HAM Kerstjens Cochrane Database of Systematic Reviews 2016 (8), 2016 | 81 | 2016 |
| Dutch Oncology COVID-19 consortium: outcome of COVID-19 in patients with cancer in a nationwide cohort study K de Joode, DW Dumoulin, J Tol, HM Westgeest, LV Beerepoot, ... European Journal of Cancer 141, 171-184, 2020 | 80 | 2020 |
| Diagnosing viral and bacterial respiratory infections in acute COPD exacerbations by an electronic nose: a pilot study WH van Geffen, M Bruins, HAM Kerstjens Journal of breath research 10 (3), 036001, 2016 | 75 | 2016 |
| Differential switching to IgG and IgA in active smoking COPD patients and healthy controls CA Brandsma, HAM Kerstjens, WH van Geffen, M Geerlings, DS Postma, ... European Respiratory Journal 40 (2), 313-321, 2012 | 60 | 2012 |
| Pleural adhesion assessment as a predictor for pneumothorax after endobronchial valve treatment WH van Geffen, K Klooster, JE Hartman, NHT Ten Hacken, ... Respiration 94 (2), 224-231, 2017 | 30 | 2017 |
| Emerging bronchoscopic treatments for chronic obstructive pulmonary disease WH van Geffen, HAM Kerstjens, DJ Slebos Pharmacology & Therapeutics 179, 96-101, 2017 | 29 | 2017 |
| Increased neutrophil expression of pattern recognition receptors during COPD exacerbations SD Pouwels, WH Van Geffen, MR Jonker, HAM Kerstjens, MC Nawijn, ... Respirology 22 (2), 401-404, 2017 | 29 | 2017 |
| Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy AL Noordhof, RAM Damhuis, LEL Hendriks, AJ de Langen, W Timens, ... Lung cancer 155, 163-169, 2021 | 28 | 2021 |
| Diagnosing non-small cell lung cancer by exhaled breath profiling using an electronic nose: a multicenter validation study S Kort, M Brusse-Keizer, H Schouwink, E Citgez, FH de Jongh, ... Chest 163 (3), 697-706, 2023 | 23 | 2023 |
| Hyperinflation in COPD exacerbations WH van Geffen, DJ Slebos, K HAM Lancet Respir Med, http://dx.doi.org/10.1016/S2213-2600(15), 2015 | 23 | 2015 |
| Timely administration of tocilizumab improves outcome of hospitalized COVID-19 patients A Rutgers, PE Westerweel, B van der Holt, S Postma, MGA van Vonderen, ... PLoS One 17 (8), e0271807, 2022 | 22* | 2022 |
| The electronic nose: emerging biomarkers in lung cancer diagnostics WH van Geffen, K Lamote, A Costantini, LEL Hendriks, NM Rahman, ... Breathe 15 (4), e135-e141, 2019 | 22 | 2019 |
| Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective … RGP Gijtenbeek, RAM Damhuis, AJ van der Wekken, LEL Hendriks, ... The Lancet Regional Health–Europe 27, 2023 | 19 | 2023 |
| Static and dynamic hyperinflation during severe acute exacerbations of chronic obstructive pulmonary disease WH van Geffen, HAM Kerstjens International journal of chronic obstructive pulmonary disease, 1269-1277, 2018 | 18 | 2018 |
| Nationwide real-world cohort study of first-line tyrosine kinase inhibitor treatment in epidermal growth factor receptor-mutated non–small-cell lung cancer RGP Gijtenbeek, RAM Damhuis, HJM Groen, AJ van der Wekken, ... Clinical lung cancer 21 (6), e647-e653, 2020 | 17 | 2020 |
| Prioritisation of treatment goals among older patients with non-curable cancer: the OPTion randomised controlled trial in Dutch primary care ME Stegmann, D Brandenbarg, AKL Reyners, WH van Geffen, ... British Journal of General Practice 70 (696), e450-e456, 2020 | 16 | 2020 |
| Risk factors for neurocognitive decline in lung cancer patients treated with prophylactic cranial irradiation: A systematic review H Zeng, LEL Hendriks, WH van Geffen, WJA Witlox, DBP Eekers, ... Cancer Treatment Reviews 88, 102025, 2020 | 15 | 2020 |
